Cannabis Ruderalis

Sylvie Garneau-Tsodikova
Alma materUniversité Laval
University of Alberta
Scientific career
InstitutionsHarvard Medical School
University of Michigan
University of Kentucky
ThesisNew antimicrobial agents acting on bacterial cell walls. (2003)

Sylvie Garneau-Tsodikova is a French Canadian-American chemist who is a Professor and Associate Vice President for Research at the University of Kentucky. One of the areas of her research interest is the development of new molecules to combat bacterial and fungal resistance.

Early life and education[edit]

Garneau-Tsodikova was born in Quebec City, Canada. She attended the Université Laval for her undergraduate studies in chemistry, where she graduated top of the class.[1] As a student, she was honoured with several awards, including distinguishments from the Chemical Institute of Canada and Natural Sciences and Engineering Research Council.[1] She completed a Master's thesis on the synthesis of glutamyl transfer RNA synthetase inhibitors.[2] She moved to the University of Alberta for graduate studies, where she worked on the impact of antimicrobial agents of bacterial cell walls.[3][4] During her doctoral studies she became interested in infectious diseases and the development of antibacterial agents.[5]

Research and career[edit]

Garneau-Tsodikova moved to the Harvard Medical School for her postdoctoral training where she worked with Christopher T. Walsh on the formation and modification of dipyrroles. At Harvard she was trained in both enzymology and biochemistry. In 2006, Garneau-Tsodikova moved to the University of Michigan, where she was an Assistant Professor of Medicinal Chemistry.[6] She spent seven years at Michigan, until she moved to the University of Kentucky. She was promoted to Professor and Assistant Dean in 2018.[7]

Garneau-Tsodikova's research focuses on the development of antifungal and antibacterial agents.[5] In particular, Garneau-Tsodikova focused on drug resistance in tuberculosis and in fungal infections by Candida auris.[5] She was also involved in the development of multifunctional enzymes with tunable biological properties. She served as an Associate Editor of the Royal Society of Chemistry journal MedChemComm, now called RSC Medicinal Chemistry.[8]

Selected publications[edit]

References[edit]

  1. ^ a b "Sylvie Garneau-Tsodikova". UK College of Pharmacy. Retrieved 2021-04-17.
  2. ^ Garneau, Sylvie (1998). Synthèse d'inhibiteurs de la glutamyl t-ARN synthétase et approche à la synthèse du striatène (Thesis) (in French). Ottawa: National Library of Canada = Bibliothèque nationale du Canada. OCLC 46552296.
  3. ^ Garneau, Sylvie (2004). New antimicrobial agents acting on bacterial cell walls (Thesis). Ottawa: National Library of Canada = Bibliothèque nationale du Canada. OCLC 56752162.
  4. ^ Howard, Kaitlind C.; Dennis, Emily K.; Watt, David S.; Garneau-Tsodikova, Sylvie (2020-04-27). "A comprehensive overview of the medicinal chemistry of antifungal drugs: perspectives and promise". Chemical Society Reviews. 49 (8): 2426–2480. doi:10.1039/C9CS00556K. ISSN 1460-4744. PMID 32140691. S2CID 212567513.
  5. ^ a b c "Sylvie Garneau-Tsodikova On Women In STEM". BioTechniques. 2020-03-24. Retrieved 2021-04-17.
  6. ^ "Sylvie Garneau-Tsodikova | Faculty History Project". faculty-history.dc.umich.edu. Retrieved 2021-04-17.
  7. ^ "Sylvie Garneau-Tsodikova, PhD", University of Kentucky, College of Pharmacy. Retrieved May 16, 2020.
  8. ^ "RSC Medicinal Chemistry Desktop Seminar Series". www.rsc.org. Retrieved 2021-04-17.

Leave a Reply